Innovative Medicine
-
-
Janssen Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for INVOKANA® (canagliflozin) to Reduce the Risk of Major Adverse Cardiovascular Events (MACE) Based on Landmark CANVAS Program
Filing includes data on the combined risk reduction of cardiovascular death, myocardial infarction and stroke in patients with type 2 diabetes -
-
-
NEW TWO-YEAR TREMFYA™ (GUSELKUMAB) DATA SHOW PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS ACHIEVED CONSISTENT RATES OF SKIN CLEARANCE
More than 80 percent of patients receiving TREMFYA™, including patients transitioned from Humira® to the anti-interleukin (IL)-23 monoclonal antibody, demonstrated PASI 90 and IGA 0/1 scores at week 100 -
JANSSEN RECEIVES CHMP POSITIVE OPINION FOR GUSELKUMAB RECOMMENDING APPROVAL FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN THE EUROPEAN UNION
Pending approval, guselkumab will be the first biologic that selectively blocks interleukin (IL)-23 -
Johnson & Johnson Announces Collaboration with U.S. Department of Health and Human Services to Fight Influenza
Janssen and Biomedical Advanced Research and Development Authority (BARDA) join forces to accelerate new therapies and vaccines to protect communities against the threat of a pandemic -
Janssen Submits Supplemental New Drug Application to U.S. FDA for ZYTIGA® (abiraterone acetate) to Treat Men with Earlier Stages of Metastatic Prostate Cancer
Filing Supported by Data from Pivotal LATITUDE Trial Evaluating ZYTIGA® in Combination with Prednisone and Androgen Deprivation Therapy (ADT) -
Johnson & Johnson Launches Dr. Paul Janssen Project to Catalyze and Convene Champions of Science Across Generations and Geographies
Shark Tank’s Daymond John to Judge the First Champions of Science “What’s New?” Challenge Multifaceted Platform to Broaden Public Engagement in Science